Test drug namodenoson for non-alcoholic fatty liver inflammation
Treatments studied
Part of Digestive system clinical trials.
This Phase 2 trial tests whether namodenoson can improve non-alcoholic steatohepatitis (NASH), a type of fatty liver inflammation. You may need two liver biopsies to see whether liver changes improve over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your liver tests show elevated AST (at least 20 IU/L).
- FibroScan results must be high (liver stiffness at least 8.5 kPa).
- NASH must be confirmed by liver biopsy, with specific biopsy scoring (NAS 4 or higher).
- Your liver scarring must be early to moderate (stage 1–3).
- Your blood work and metabolism must fit specific targets (albumin, INR, bilirubin, and blood counts), and you must meet at least 2 metabolic syndrome criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether SNP-610 (or a placebo) can improve non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. It also checks safety by comparing outcomes between the two groups.
This study checks whether an MRI scan can measure liver health in people with suspected fatty liver disease that may have progressed to NASH. Everyone in the study is also scheduled for a standard liver biopsy, which is used to compare the scan results.
This trial tests whether multiple injections of B1344 are safe and tolerable in people with nonalcoholic fatty liver disease (NAFLD). It aims to find the right dose and check how the drug works in the body.
This Phase 3 trial studies whether namodenoson can slow or control advanced hepatocellular carcinoma (liver cancer) in people whose cirrhosis is in a specific middle range. It may help if standard treatments have not worked or the cancer has spread and is not expected to be cured.
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
Hear when a new NASH - Nonalcoholic Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.